Skip to content

Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors

A Pilot Study of the Effects of Replacing Orange Carrots and White Potatoes With Purple Varieties, on Risk Factors for Cardiovascular Disease

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01564498
Enrollment
60
Registered
2012-03-27
Start date
2012-04-30
Completion date
2017-12-31
Last updated
2016-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia, Hypertension, Inflammation, Obesity, Type II Diabetes

Keywords

anthocyanins, antioxidant, polyphenols, bioavailability, cholesterol, insulin sensitivity, glucose tolerance, atherosclerosis, metabolic syndrome

Brief summary

The hypothesis is that richly coloured purple vegetables, rich in polyphenolic compounds including anthocyanins will have higher antioxidant and other biological activities, than more lightly coloured versions of these foods. Diets of human subjects will be modified to allow consumption of 200-300 g of raw carrots or cooked potatoes. Participants will be randomized to consume either orange or purple carrots, or white or purple potatoes. They will consume these diets for 12 weeks and bioavailability of polyphenolics will be examined as well as anthropometry and blood biochemistry for changes in risk factors associated with cardiovascular disease.

Interventions

OTHERvegetable

200-300 g raw carrots or 300-500 g cooked potatoes

Sponsors

Ontario Ministry of Agriculture, Food and Rural Affairs
CollaboratorOTHER_GOV
University of Guelph
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* adult men and women 18-65 years of age * must have a least one of the following risk factors associated with increased risk of type II diabetes and/or cardiovascular disease: * borderline high or hypertension or undergoing treatment for such * abnormal fasting blood glucose or undergoing treatment for such * overweight or obese * borderline high or high LDL-cholesterol or undergoing treatment for such * borderline low or low HDL-cholesterol * borderline high or high triglycerides or undergoing treatment for such

Exclusion criteria

* smokers, pregnant or nursing women

Design outcomes

Primary

MeasureTime frameDescription
Blood cholesterol12 weeksblood will be collected at baseline before the experimental foods are introduced and again 6 weeks into the intervention period and during the last week of the intervention (week 12)

Secondary

MeasureTime frameDescription
blood pressure12 weeksParticipants will have their body weight and blood pressure taken at weekly counselling sessions
body composition12 weeksbody composition will be measured in well hydrated subjects using bioelectric impedence analysis
insulin resistance12 weeksinsulin resistance will be measured by way of an oral glucose tolerance test and collection of venous blood samples for the subsequent 3 hours on two occasions, baseline and during the last week of the intervention diet.
blood and urinary polyphenol metabolites12 weeksvenous blood and urine will be collected to determine the metabolic profiles of polyphenolics in individual participants. Based on intake data, the bioavailability of the polyphenols in the foods will be estimated.
circulating biomarkers of cardiovascular disease and type II diabetes risk12 weeksBlood will be collected for measurement of multiple cytokines, growth factors and other blood biomarkers associated with these diseases.

Countries

Canada

Contacts

Primary ContactKelly A Meckling, PhD
kmecklin@uoguelph.ca5198244120
Backup ContactSaqib Mannan, BSc
smannan@uoguelph.ca5198244120

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026